Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of PA-824 when given
with a single dose of midazolam, and to determine whether PA-824 inhibits CYP3A to a
clinically important degree as measured by the effect of PA-824 on the pharmacokinetics of
midazolam, a known CYP3A substrate.